

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 15670-0198US1	Application No. 10/571,510
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Yitzhak Tor et al.	
		Filing Date December 8, 2006	Group Art Unit 1623

**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
/E.P./	1	4,160,452	7/10/1979	Theeuwes			
/E.P./	2	4,256,108	3/17/1981	Theeuwes			
/E.P./	3	4,265,874	5/5/1981	Bonsen et al.			
/E.P./	4	4,749,800	06/07/1988	Jobe et al.			

**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
/E.P./	5	WO 2005/025513	3/24/2005	WIPO				

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
/E.P./	6	U.S. Examiner Elli Peselev, International Search Report and Written Opinion dated July 20, 2005 for PCT/US04/29880, filed September 10, 2004, (8 pages)
/E.P./	7	Baba, M. et al., "HIV-1-Specific Reverse Transcriptase Inhibitors," Chapter 11 in Anti-AIDS Drug Development: Challenges, Strategies and Prospects, P. Mohan and M. Baba (Editors), Harwood Academic Publishers GmbH, Switzerland, 1995, pp. 239-267
/E.P./	8	Baker, T.J. et al., "Synthesis and Anti-HIV activity of Guanidinoglycosides," J. Org. Chem., 65: 9054-9058 (2000)
/E.P./	9	Check, E., "HIV Drug Resistance Triggers Strategic Switch," Nature 424: 361 (July 24, 2003)
/E.P./	10	De Clercq, Erik, "From Anti-HIV Agents to Anti-AIDS Chemotherapy: A Critical Appraisal," Chapter 1 in Anti-AIDS Drug Development: Challenges, Strategies and Prospects, P. Mohan and M. Baba (Editors), Harwood Academic Publishers GmbH, Switzerland, 1995, pp. 1-37
/E.P./	11	Frankel, A.D. and J.A.T. Young, "HIV-1: Fifteen Proteins and an RNA," Annu. Rev. Biochem. 67: 1-25 (1998)
/E.P./	12	Greenwald, R.B. et al., "Drug Delivery Systems employing 1,4- or 1,6-Eliminations: Poly(ethylene glycol) Prodrugs of Amino-containing Compounds," J. Med. Chem. 42: 3657-3667 (1999)
/E.P./	13	Jeong, L.S. et al., "Nucleosides and Derivative," Chapter 2 in Anti-AIDS Drug Development: Challenges, Strategies and Prospects, P. Mohan and M. Baba (Editors), Harwood Academic Publishers GmbH, Switzerland, 1995, pp. 39-63
/E.P./	14	Kirk, S.R. et al., "Neomycin-Acridine Conjugate: A Potent Inhibitor of Rev-RRE Binding," J. Am. Chem. Soc. 122: 980-981 (2000)
/E.P./	15	Luedtke, N.W. and Y. Tor, "A Novel Solid-Phase Assembly for Identifying Potent and Selective RNA Ligands," Angew. Chem. Int. Ed. 39(10): 1788-1790 (2000)
/E.P./	16	Luedtke, N.W. et al., "Guanidinoglycosides: A Novel Family of RNA Ligands," J. Am. Chem. Soc. 122: 12035-12036 (2000)
/E.P./	17	Pollard, V.M. and M.H. Pollard, "The HIV-1 Rev Protein" Annu. Rev. Microbiol. 52: 491-532 (1998)

Examiner Signature /Elli Peselev/	Date Considered 03/18/2010
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 15670-0198US1	Application No. 10/571,510
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Yitzhak Tor et al.	
		Filing Date December 8, 2006	Group Art Unit 1623
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
/E.P./	18	Joint United Nations Programme on HIV/AIDS (UNAIDS), <i>Report on the Global HIV/AIDS Epidemic 2002</i> , Switzerland, UNAIDS/02.26E, ISBN 92-1973-185-4, 229 pages (July 2002)
/E.P./	19	Wakselman, M., "1,4- and 1,6-eliminations from hydroxyl and amino-substituted benzyl systems: chemical and biochemical applications," <i>Nouveau Journal De Chimie</i> , 7(7): 439-447 (July 1983)
/E.P./	20	Wang, H. And Y. Tor, "Dimeric Aminoglycosides: Design, Synthesis and RNA Binding," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , 7(14): 1951-1956 (1997)
/E.P./	21	Wang, H. and Y. Tor, "Tobramycin-EDTA Conjugate: A Noninnocent Affinity-Cleaving Reagent," <i>Bioorg. Med. Chem. Lett.</i> (1998) 8: 3665-3670 (1998)
/E.P./	22	Wang, H. and Y. Tor, "Electrostatic Interactions in RNA Aminoglycosides Binding," <i>J. Am. Chem Soc.</i> 119:8734-8735 (1997)

Examiner Signature /Elli Peselev/	Date Considered 03/18/2010
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	